anti cd352 antibody drug conjugate sgn cd352a

Drug Overview

The medication known as anti cd352 antibody drug conjugate sgn cd352a (also identified as SGN-CD352A) is an investigational “smart bomb” therapy designed to treat B-cell malignancies, primarily Multiple Myeloma. It is an Antibody-Drug Conjugate (ADC), a class of drugs that combines the precision of a monoclonal antibody with the extreme cell-killing power of a chemotherapy payload.

Developed by Seagen (formerly Seattle Genetics, now part of Pfizer), SGN-CD352A targets CD352 (also known as SLAMF6), a protein found on the surface of plasma cells and many B-cell cancers. By delivering a lethal toxin directly into these specific cells, the drug aims to destroy the cancer while minimizing the systemic “collateral damage” typically associated with traditional, non-targeted chemotherapy.

• Generic Name: SGN-CD352A.
• Drug Class: Antibody-Drug Conjugate (ADC) / DNA-Alkylating Agent.
• Target: CD352 (SLAMF6 / Ly108).
• Payload: Pyrrolobenzodiazepine (PBD) dimer.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational/Discontinued. As of March 2026, SGN-CD352A is not FDA-approved. Clinical development was largely halted following early-phase trials (such as NCT02951156). While the drug showed biological activity, the therapeutic window—the balance between effectiveness and safety—proved challenging due to the high potency of the PBD payload and the target’s expression on some healthy immune cells.

What Is It and How Does It Work? (Mechanism of Action)

The CD352 (SLAMF6) Target

CD352 is a cell-surface protein belonging to the Signaling Lymphocyte Activation Molecule (SLAM) family. It is highly and consistently expressed on Multiple Myeloma cells. In healthy individuals, it is primarily found on certain white blood cells, which allows the drug to be reasonably selective for the “factory” cells involved in myeloma.

Molecular Level Mechanisms

1. Selective Binding: After infusion, SGN-CD1352A circulates and binds with high affinity to the CD352 receptor on the surface of the myeloma cell.
2. Internalization: The cancer cell “swallows” the drug-receptor complex (endocytosis), transporting it to the lysosome.
3. Payload Release: Inside the lysosome, the chemical linker is cleaved, releasing the active toxin—a pyrrolobenzodiazepine (PBD) dimer.
4. DNA Cross-linking: PBD dimers are among the most potent cytotoxic agents known. They bind to the “minor groove” of the DNA and form irreversible cross-links between the two strands of the DNA ladder.
5. Apoptosis: This damage “handcuffs” the DNA, making it impossible for the cell to unzip its genetic code to replicate. This leads to cell cycle arrest and triggers apoptosis (programmed cell death).

FDA Approved Clinical Indications

There are currently no FDA-approved clinical indications for SGN-CD352A.

During its clinical testing, it was primarily investigated for:

• Relapsed or Refractory Multiple Myeloma: For patients who had failed multiple prior lines of therapy, including proteasome inhibitors and immunomodulatory drugs.

Dosage and Administration Protocols

Because the drug did not move past early-phase testing, there is no established “Standard of Care” dose. The following reflect the experimental protocols used during its Phase I research.

Clinical Efficacy and Research Results

The clinical journey of SGN-CD352A provided critical lessons for the future of Multiple Myeloma treatment.

• Potent Cytotoxicity: Preclinical data showed that SGN-CD352A was effective at killing myeloma cells at extremely low concentrations, even in models that were resistant to standard treatments.
• Clinical Challenges: In human trials, while some patients showed evidence of tumor reduction, the drug was associated with “cumulative toxicity.” This means the side effects became more difficult for the body to manage with each subsequent dose.
• Development Pivot: The lessons learned from the SGN-CD352A program helped researchers refine newer ADCs that use less toxic payloads or more stable linkers, leading to modern successes like Belantamab Mafodotin.

Safety Profile and Side Effects

The primary challenge with SGN-CD352A related to the PBD payload, which can impact healthy tissues if it persists in the body.

Common Side Effects (>20%):

• Fatigue: A general sense of tiredness.
• Nausea: Usually manageable with anti-emetics.
• Peripheral Edema: Swelling in the ankles or legs.

Serious Adverse Events:

• Myelosuppression: Significant drops in white blood cells (neutropenia) and platelets (thrombocytopenia), increasing the risk of infection and bleeding.
• Hepatotoxicity: Elevation of liver enzymes, which was a “dose-limiting” factor in several trials.
• Vascular Leak Syndrome: A rare but serious condition where fluid leaks from small blood vessels, leading to swelling and potentially low blood pressure.

Research Areas

In the field of Stem Cell and Regenerative Medicine, SGN-CD352A is studied as part of the “Plasma Cell Niche” research. CD352 is vital for the interaction between plasma cells and the bone marrow environment. Researchers use the data from SGN-CD352A trials to understand how to “clear the niche” of malignant cells before a Hematopoietic Stem Cell Transplant. By destroying the cancerous plasma cells in their home environment, scientists hope to improve the “take” rate of new, healthy stem cells.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• CD352 Expression Screening: Confirmation of the target on tumor cells via biopsy or flow cytometry.
• Baseline Liver and Kidney Panels: To ensure the organs can safely process the drug.
• Coagulation Profile: Monitoring the blood’s ability to clot due to potential platelet impacts.

Precautions:

• Fluid Monitoring: Patients should track their weight daily; sudden gain can indicate fluid retention or vascular leak.
• Infection Prevention: Avoid crowds and maintain strict hygiene during periods of low white blood cell counts.

“Do’s and Don’ts” List:

• DO report any yellowing of the eyes (jaundice) or dark urine immediately.
• DO keep a thermometer at home and report a fever over 100.4°F (38°C) instantly.
• DON’T ignore sudden swelling in the face or extremities.
• DON’T start new medications or supplements without oncology approval, as they may stress the liver further.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. SGN-CD352A is an inactive investigational agent and is not approved by the FDA for any indication. Always consult with a qualified hematologist-oncologist regarding currently available and approved treatments for Multiple Myeloma.